ANNJI PHARMACEUTICAL CO., LTD.
🇹🇼Taiwan
- Country
- 🇹🇼Taiwan
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.ajpharm.com
Clinical Trials
3
Active:0
Completed:2
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AJ302-IM in Healthy Volunteers
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- AnnJi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 56
- Registration Number
- NCT06625541
- Locations
- 🇺🇸
AnnJi Investigational Site, Miami, Florida, United States
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of AJ201 In Patients
Phase 1
Completed
- Conditions
- Spinal and Bulbar Muscular AtrophyKennedy's Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-08-26
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- AnnJi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 25
- Registration Number
- NCT05517603
- Locations
- 🇺🇸
University of California, Irvine, Orange, California, United States
🇺🇸Stanford University, Palo Alto, California, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
A Study to Investigate the Safety, Tolerability, Pharmacokinetics of ALZ002 DS in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: ALZ002 DSDrug: Placebo
- First Posted Date
- 2020-05-19
- Last Posted Date
- 2021-08-18
- Lead Sponsor
- AnnJi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 72
- Registration Number
- NCT04392830
- Locations
- 🇦🇺
Cmax clinical research, Adelaide, Australia
News
No news found